Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
269.03
+1.75 (0.65%)
Sep 17, 2026, 12:10 PM EDT - Market open
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $25.31B in the quarter ending June 30, 2026, with 6.60% growth. This brings the company's revenue in the last twelve months to $97.93B, up 8.06% year-over-year. In the year 2025, Johnson & Johnson had annual revenue of $94.19B with 6.05% growth.
Revenue (ttm)
$97.93B
Revenue Growth
+8.06%
P/S Ratio
6.61
Revenue / Employee
$708,603
Employees
138,200
Market Cap
648.34B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 94.19B | 5.37B | 6.05% |
| Dec 31, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 31, 2019 | 82.06B | 478.00M | 0.59% |
| Dec 31, 2018 | 81.58B | 5.13B | 6.71% |
| Dec 31, 2017 | 76.45B | 4.56B | 6.34% |
| Jan 1, 2017 | 71.89B | 1.82B | 2.59% |
| Jan 3, 2016 | 70.07B | -4.26B | -5.73% |
| Dec 31, 2014 | 74.33B | 3.02B | 4.23% |
| Dec 31, 2013 | 71.31B | 4.09B | 6.08% |
| Dec 30, 2012 | 67.22B | 2.19B | 3.37% |
| Jan 1, 2012 | 65.03B | 3.44B | 5.59% |
| Jan 2, 2011 | 61.59B | -310.00M | -0.50% |
| Jan 3, 2010 | 61.90B | -1.85B | -2.90% |
| Dec 28, 2008 | 63.75B | 2.65B | 4.34% |
| Dec 30, 2007 | 61.10B | 7.77B | 14.57% |
| Dec 31, 2006 | 53.32B | 2.81B | 5.56% |
| Jan 1, 2006 | 50.51B | 3.17B | 6.69% |
| Jan 2, 2005 | 47.35B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Eli Lilly and Company | 79.67B |
| Merck & Co. | 66.57B |
| AbbVie | 64.39B |
| Pfizer | 63.70B |
| AstraZeneca | 61.37B |
| Novartis AG | 56.69B |
| Sanofi | 55.89B |
| Novo Nordisk | 50.34B |
JNJ News
- 2 days ago - RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026 - PRNewsWire
- 2 days ago - Contineum, J&J's depression drug fails to meet mid-stage trial goal - Reuters
- 3 days ago - Johnson & Johnson Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 3 days ago - Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer - PRNewsWire
- 4 days ago - J&J Is In Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion - WSJ
- 5 days ago - Apollo Global in talks to acquire J&J's orthopedics unit, Bloomberg News reports - Reuters
- 7 days ago - Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses - Business Wire
- 8 days ago - Johnson & Johnson Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts